Sinocare (300298) Fundamentals 2026 — P/E 73.3x, Revenue Analysis | SniperIQ
Sinocare (300298) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of ¥8.8B, trading at ¥15.76 on the SHZ. This SniperIQ fundamentals page covers Sinocare's valuation (P/E 73.3x, P/B 2.8x), profitability (net margin 2.4%), revenue (¥4.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sinocare's market cap?
Sinocare (300298) has a market capitalization of approximately ¥8.8B, trading at ¥15.76 on the SHZ. Market cap moves with the live share price.
What is Sinocare's P/E ratio?
Sinocare's trailing twelve-month P/E ratio is 73.3x, with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sinocare?
Sinocare runs a net profit margin of 2.4%, a gross margin of 49.8%, and an operating margin of 1.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sinocare generate?
Sinocare reported revenue of ¥4.7B for fiscal year 2025, with net income of ¥93M and earnings per share (EPS) of 0.17. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sinocare pay a dividend?
Sinocare does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Sinocare financially healthy?
Sinocare carries a debt-to-equity ratio of 0.10x and a current ratio of 1.19x, with a market beta of -0.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sinocare a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sinocare (300298) the key facts are: market cap ¥8.8B, P/E 73.3x, revenue ¥4.7B, 52-week range 13.37-23.96. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sinocare's full fundamentals live
Get Sinocare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.